SynthesisThe Cochrane database of systematic reviews2008
Amantadine and rimantadine for influenza A in children and the elderly.
Synthesis in The Cochrane database of systematic reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 6 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Amantadine and rimantadine for influenza A in children and the elderly.The Cochrane database of systematic reviews · 2014Pooled it
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.The Cochrane database of systematic reviews · 2014Pooled it
- Aminoadamantanes for chronic hepatitis C.The Cochrane database of systematic reviews · 2014Pooled it
- Chinese medicinal herbs for influenza.The Cochrane database of systematic reviews · 2013Pooled it
- Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.Annals of internal medicine · 2012Pooled it
- Influenza.BMJ clinical evidence · 2009Pooled it
- Pathogenesis of MRSA-influenza co-infection: implications for ECMO therapeutic strategies - a mini-review.Frontiers in immunology · 2026Review
- Article
- Antivirotics based on defective interfering particles: emerging concepts and challenges.Frontiers in cellular and infection microbiology · 2025Review
- Article
- An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil.Science advances · 2024Article
- Amantadine Toxicity inToxics · 2023Article
- Synthesis and Crystal Structure of Adamantylated 4,5,6,7-Tetrahalogeno-1Molecules (Basel, Switzerland) · 2022Article
- Dynamic Propagation and Impact of Pandemic Influenza A (2009 H1N1) in Children: A Detailed Review.Current microbiology · 2020Review
- Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.Computers in biology and medicine · 2020Article
- Optimization of 4-Aminopiperidines as Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir.Journal of medicinal chemistry · 2020Article
- Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors.Frontiers in microbiology · 2020Article
- The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Allergy · 2018Review
- A travelling camper with a spiking fever, headache, myalgia, hepatitis, and intracellular inclusions.The Lancet. Infectious diseases · 2017Article
- Antiviral Treatments.Clinics in chest medicine · 2017Review
Corrections and comments
- Updated by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough amantadine (AMT) and rimantadine (RMT) are used to relieve or treat influenza A symptoms in healthy adults, little is known about the effectiveness and safety of these antivirals in preventing and treating influenza A in children and the elderly.
objectivesThe aim of this review was to systematically consider evidence on the effectiveness and safety of AMT and RMT in preventing and treating influenza A in children and the elderly. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2007, issue 3); MEDLINE (1966 to July 2007) and EMBASE (1980 to July 2007). SELECTION CRITERIA: Randomised or quasi-randomised trials comparing AMT and/or RMT in children and the elderly with placebo, control, other antivirals or comparing different doses or schedules of AMT and/or RMT or no intervention. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion and assessed methodological quality. Disagreements were resolved by consensus. In all comparisons except for one, the trials in children and in the elderly were analysed separately. Data were analysed and reported using Cochrane Review Manager 4.2. software. MAIN
resultsIn children, RMT was effective in the abatement of fever on day three of treatment. AMT showed a prophylactic effect against influenza A infection. AMT and RMT were not related to an increase in the occurrence of adverse effects. RMT also was considered to be well tolerated by the elderly, but showed no prophylactic effect. Different doses were comparable in the prophylaxis of influenza in the elderly, as well as in reporting adverse effects. Zanamivir prevented influenza A more effectively than RMT in the elderly. AUTHORS'
conclusionsAMT was effective in the prophylaxis of influenza A in children. As confounding matters might have affected our findings, caution should be taken when considering which patients should to be given this prophylactic. Our conclusions about effectiveness of both antivirals for the treatment of influenza A in children were limited to a proven benefit of RMT in the abatement of fever on day three of treatment. Due to the small number of available studies we could not reach a definitive conclusion on the safety of AMT or the effectiveness of RMT in preventing influenza in children and the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.